Nicholas Theodore, MD, was named as the principal investigator for a post-market trial evaluating Aclarion's Nociscan for diagnosing back pain.
Nociscan will be compared to standard disgnostic imaging and physical exams to decide which discs to treat, according to a May 2 news release from Aclarion. Nociscan is the first evidence-supported SaaS platform to help physicians identify painful and nonpainful discs in the lumbar spine.
"Diagnosing the source of chronic low back pain has been an industry conundrum for decades," Dr. Theodore said in the release. "Moreover, as clinicians, we are challenged by important limitations with alternative diagnostic tools like MRI and discography. Aclarion’s Nociscan tool has already illustrated a unique and compelling capability for objectively measuring pain-generating chemical biomarkers in the lumbar spine, and I am equally interested in how it may apply to measuring disc degeneration. I believe these innovations will become foundational to the diagnosis and treatment of chronic low back pain."
Dr. Theodore is the director of the neurological spine center at Johns Hopkins in Baltimore.